Literature DB >> 21711391

Association and evolutionary studies of the melatonin receptor 1B gene (MTNR1B) in the self-contained population of Sorbs from Germany.

K Dietrich1, S Birkmeier, D Schleinitz, J Breitfeld, B Enigk, I Müller, Y Böttcher, T Lindner, M Stumvoll, A Tönjes, P Kovacs.   

Abstract

AIMS: Several polymorphisms of the melatonin receptor 1B gene (MTNR1B) have been shown to be associated with elevated fasting plasma glucose and impaired early insulin release. The aim of this study was to assess the effects of MTNR1B variants on traits related to the metabolic syndrome in the self-contained population of Sorbs from Germany. As comprehensive studies concerning the conservation of MTNR1B are lacking, we also evaluated natural selection in vertebrates and human populations at this locus.
METHODS: Five single nucleotide polymorphisms representing all blocks of linkage disequilibrium within and surrounding the MTNR1B locus were genotyped in 937 Sorbs for association analyses on metabolic traits related to Type 2 diabetes. The associations were assessed by regression analyses, the conservation between species was investigated with phylogenetic analysis by maximum likelihood (PAML). In addition, various tests of population genetic measures (e.g. fixation index, Tajima's D) were performed.
RESULTS: Previously reported association between MTNR1B variants (rs10830963, rs4753426) and oral glucose tolerance test-derived indices of β-cell function (homeostasis model assessment-B, P = 3.7 × 10⁻⁶ and P = 0.004, respectively), as well as insulin (fasting insulin: P=2×10⁻³ and P=0.02; 30-min insulin: P = 2.1 × 10⁻⁴ and P=0.03, respectively) and fasting glucose (rs10830963, P=1.2×10⁻⁶) parameters could be replicated in the present study. Phylogenetic analysis by maximum likelihood analyses showed that the gene was strongly conserved between species (ω=0.2583). Structures important for the receptor function are also conserved. On the lineage leading to human adaptive selection was present (ω=1.1030). Population genetic measures further indicated natural selection.
CONCLUSIONS: Our data support the physiologic importance of MTNR1B in the context of glucose homeostasis and suggest evidence of selection at this locus.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21711391     DOI: 10.1111/j.1464-5491.2011.03374.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

Review 1.  Tired of diabetes genetics? Circadian rhythms and diabetes: the MTNR1B story?

Authors:  Cecilia Nagorny; Valeriya Lyssenko
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

Review 2.  Artificial intelligence perspective in the future of endocrine diseases.

Authors:  Mandana Hasanzad; Bagher Larijani; Hamid Reza Aghaei Meybodi; Negar Sarhangi
Journal:  J Diabetes Metab Disord       Date:  2022-01-11

Review 3.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

Authors:  Stefano Comai; Gabriella Gobbi
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

Review 4.  Melatonin in type 2 diabetes mellitus and obesity.

Authors:  Angeliki Karamitri; Ralf Jockers
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

5.  Association between the melatonin receptor 1B gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis.

Authors:  Qing Xia; Zi-Xian Chen; Yi-Chao Wang; Yu-Shui Ma; Feng Zhang; Wu Che; Da Fu; Xiao-Feng Wang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

6.  Large scale meta-analyses of fasting plasma glucose raising variants in GCK, GCKR, MTNR1B and G6PC2 and their impacts on type 2 diabetes mellitus risk.

Authors:  Haoran Wang; Lei Liu; Jinzhao Zhao; Guanglin Cui; Chen Chen; Hu Ding; Dao Wen Wang
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.